LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment
Status:
Completed
Trial end date:
2018-07-06
Target enrollment:
Participant gender:
Summary
To investigate the efficacy and safety of BIBW 2992 in combination with vinorelbine i.v.
chemotherapy as treatment in patients with HER2-overexpressing, metastatic breast cancer, who
failed one prior trastuzumab (Herceptin®) treatment